The headline ran this week in a dozen variants across the science-news ecosystem, promising “the secret reason some cancer treatments stop working.” It is a good headline. It is also four months old, and the antibody at the center of it has never been given to a person.

The study underneath the cycle, SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer, went up in Nature on February 11, 2026, out of André Veillette’s lab at the Montreal Clinical Research Institute. The Université de Montréal posted its own release the same day. EurekAlert pushed it. Then the cycle moved on, the way it does. This week the wires picked it back up, and the ScienceDaily writeup, dated June 9, is essentially the IRCM kit with a new dateline, time-released into the feed as if the discovery happened on Sunday.

What the paper actually shows is worth saying plainly, because the framing keeps obscuring it. T cells carry a surface molecule called SLAMF6 that latches onto itself, T-cell-on-T-cell, and quiets the response from the inside. PD-1 and CTLA-4, the workhorse targets behind the first wave of checkpoint inhibitors in U.S. oncology, only fire when the tumor or a stromal partner shows up to engage them. SLAMF6, in the Veillette team’s account, does not need the tumor in the room. It is a brake the T cell pulls on itself, and their contribution is a new monoclonal antibody that blocks the cis interaction and that they report outperforms every existing tool aimed at the same receptor. In mice.

That last detail does not survive the trip through the wire. The IRCM’s own announcement calls the results “remarkable” and reports “strong anti-tumour responses,” and stops there. Which mouse tumor models. How many animals per arm. The absolute reduction in tumor volume. Whether the antibody was paired with anti-PD-1 in a model where anti-PD-1 alone fails, which is the actual clinical question. None of it is in the press materials. Those omissions are not academic. They are the gap between a promising mouse experiment and any claim that bears on the patient whose checkpoint inhibitor stopped working.

The press kit is also quiet on the questions any reporter covering a “next generation” cancer therapy ought to be asking out loud. Has the IRCM filed patents on the antibody? Is there a startup vehicle, an option agreement, a licensing partner already lined up? Generations of therapy tend to arrive with intellectual property attached, and silence in a press kit is its own kind of answer. Veillette’s own framing in the UdeM piece is that the next step is to launch early-phase clinical trials, which by itself locates the work on the pipeline: Phase I has not started, no Veillette SLAMF6 trial yet shows up on the public registries, and a drug label sits years past whenever Phase I does.

SLAMF6 has been on cancer immunology’s radar a good while. An Israeli group at Hadassah, Jerusalem published the first in-vivo evidence that targeting SLAMF6 boosts CD8 T-cell anti-melanoma activity eight years ago, with CIHR money in the acknowledgments. A 2020 eLife paper characterized SLAMF6-deficient T cells as more lethal effectors. The “secret” is the kind of secret that has had a lit shelf for the better part of a decade. What Veillette’s team has added is a cleaner, harder-hitting antibody, validated in a mouse, with a credible mechanism for working in the patients who never responded to checkpoint blockade in the first place.

That is a legitimate piece of preclinical work, and it earns the Nature slot it got. The Canadian funders behind it (CIHR, the Terry Fox Research Institute, BioCanRx, Québec’s economy ministry, the Canadian Foundation for Innovation) are public money, which in this field counts as relatively clean provenance, and the underlying paper is straight about what is left to do. The trouble is downstream. By the time a four-month-old mouse study has been rebranded as this week’s miracle, the distance between what the science says (a familiar target, a better tool, a rodent) and what the patient hears (the secret reason cancer drugs stop working has been found) is wide enough to fall through.

A useful rule, when a headline promises a secret: check the dateline on the paper.

Sources

  1. Nature – Veillette et al., “SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer” (Feb 11, 2026)
  2. Université de Montréal news release (Feb 11, 2026)
  3. IRCM press release on the SLAMF6 work
  4. EurekAlert release of the IRCM kit
  5. ScienceDaily, recycled June 9, 2026 writeup
  6. Eisenberg et al., Clinical Cancer Research (2018), targeting SLAMF6 and anti-melanoma activity
  7. Hajaj et al., eLife (2020), SLAMF6 deficiency as a T-cell checkpoint